<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39328842</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2052-3211</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Journal of pharmaceutical policy and practice</Title><ISOAbbreviation>J Pharm Policy Pract</ISOAbbreviation></Journal><ArticleTitle>Trends in medicine utilisation in public and private healthcare facilities before and during COVID-19: a nationwide analysis of medicine procurement and sales data, 2018-2022.</ArticleTitle><Pagination><StartPage>2401468</StartPage><MedlinePgn>2401468</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2401468</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/20523211.2024.2401468</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">There was a fluctuation in medication demand and supply during COVID-19 pandemic. This study aimed to assess the trend of drug utilisation in Malaysia in 2018-2022 and evaluate the impact of COVID-19 on drug utilisation rates.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a repeated cross-sectional study of pharmaceutical sales data from public and private sectors in Malaysia from 2018 to 2022. Drug utilisation rates for the period after the onset of COVID-19 (2020-2022) was compared with the earlier period (2018-2019). Interrupted time-series regression analyses evaluated level and slope changes compared to pre-COVID-19 pandemic level for quarterly rates of drugs utilisation in public and private sectors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There was an immediate reduction in the utilisation rates for all drugs after COVID-19 in public (-20.4%; <i>p</i> = 0.043) and private sectors (-22.4%; <i>p</i> = 0.003). In both sectors, significant level changes were observed for anti-infectives, musculoskeletal, neurological, respiratory, and sensory organs preparations following COVID-19 pandemic, followed by a sustained increase in trend from 2020 to 2022. Public sector had a 22.2% reduction in the utilisation of cardiovascular drugs (<i>p</i> = 0.002), particularly for renin-angiotensin system (RAS) agents (-47.4%, <i>p</i> = 0.019). Private sector had large changes for anti-infectives (-53.6%, <i>p</i> &lt; 0.001) and neurological drugs (-51.4%, <i>p</i> &lt; 0.001), driven by an immediate level reduction in antibacterials (-54.2%, <i>p</i> &lt; 0.001) and cough and cold preparations (-59.2%, <i>p</i> &lt; 0.001). Classes with agents used for COVID-19 treatment, such as systemic corticosteroids, antibiotics, and antivirals had an increasing trend between April 2020 and December 2022, although some slope changes were not statistically significant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">A significant reduction in the overall drug utilisation rates was observed in the public and private sectors in Malaysia as an immediate impact of the COVID-19 pandemic in 2020. The impacts varied by therapeutic class and health sector. This finding provides an understanding of the changing patterns of drug utilisation that were affected by disease outbreaks for future planning of pandemic preparedness.</AbstractText><CopyrightInformation>© 2024 Ministry of Health Malaysia. Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ab Rahman</LastName><ForeName>Norazida</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-6439-2005</Identifier><AffiliationInfo><Affiliation>Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Low</LastName><ForeName>Ee Vien</ForeName><Initials>EV</Initials><Identifier Source="ORCID">0000-0001-8596-1318</Identifier><AffiliationInfo><Affiliation>Institute for Health Systems Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Audrey Huili</ForeName><Initials>AH</Initials><Identifier Source="ORCID">0000-0001-6721-1505</Identifier><AffiliationInfo><Affiliation>Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad Shanizza</LastName><ForeName>Azzy Iyzati</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0003-0368-0227</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Services Programme, Ministry of Health Malaysia, Petaling Jaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>See Wan</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Pharmaceutical Services Programme, Ministry of Health Malaysia, Petaling Jaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamal</LastName><ForeName>Mardhiyah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaceutical Services Programme, Ministry of Health Malaysia, Petaling Jaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamad Yahaya</LastName><ForeName>Abdul Haniff</ForeName><Initials>AH</Initials><Identifier Source="ORCID">0000-0002-4591-7053</Identifier><AffiliationInfo><Affiliation>Pharmaceutical Services Programme, Ministry of Health Malaysia, Petaling Jaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivasampu</LastName><ForeName>Sheamini</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2314-6048</Identifier><AffiliationInfo><Affiliation>Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pharm Policy Pract</MedlineTA><NlmUniqueID>101627192</NlmUniqueID><ISSNLinking>2052-3211</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Drug utilisation</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39328842</ArticleId><ArticleId IdType="pmc">PMC11425687</ArticleId><ArticleId IdType="doi">10.1080/20523211.2024.2401468</ArticleId><ArticleId IdType="pii">2401468</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aboulatta, L., Peymani, P., Vaccaro, C., Leong, C., Kowalec, K., Delaney, J., Falk, J., Alessi-Severini, S., Aloud, B., &amp; Eltonsy, S. (2022). Drug utilization patterns before and during COVID-19 pandemic in Manitoba, Canada: A population-based study. PLoS ONE, 17(11), e0278072. 10.1371/journal.pone.0278072</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0278072</ArticleId><ArticleId IdType="pmc">PMC9704650</ArticleId><ArticleId IdType="pubmed">36441676</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Zoubi, S., Gharaibeh, L., Jaber, H. M., &amp; Al-Zoubi, Z. (2021). Household drug stockpiling and panic buying of drugs during the COVID-19 pandemic: A study from Jordan. Frontiers in Pharmacology, 12, 813405. 10.3389/fphar.2021.813405</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.813405</ArticleId><ArticleId IdType="pmc">PMC8730317</ArticleId><ArticleId IdType="pubmed">35002744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang, Z. Y., Cheah, K. Y., Shakirah, M. S., Fun, W. H., Anis-Syakira, J., Kong, Y. L., … Sararaks, S. (2021). Malaysia's health systems response to COVID-19. International Journal of Environmental Research &amp; Public Health, 18(21), 11109. 10.3390/ijerph182111109</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph182111109</ArticleId><ArticleId IdType="pmc">PMC8583455</ArticleId><ArticleId IdType="pubmed">34769629</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora, I., White, S., &amp; Mathews, R. (2023). Global dietary and herbal supplement use during COVID-19 – a scoping review. Nutrients, 15(3), 3. 10.3390/nu15030771</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15030771</ArticleId><ArticleId IdType="pmc">PMC9920285</ArticleId><ArticleId IdType="pubmed">36771480</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzeri, A., Abdul Hakim, N. F., Jaafar, M. H., Dahlui, M., Othman, S., &amp; Tunku Zainol Abidin, T. K. Z. (2021). The impact of movement control order during COVID-19 pandemic on healthcare utilisation: How does the projected patient workload compared to the actual number of patients in care? Journal of Health and Translational Medicine, Special Issue Covid-19(1), 22. 10.22452/jummec.sp2021no1.4</Citation><ArticleIdList><ArticleId IdType="doi">10.22452/jummec.sp2021no1.4</ArticleId></ArticleIdList></Reference><Reference><Citation>Chini, F., Pezzotti, P., Orzella, L., Borgia, P., &amp; Guasticchi, G. (2011). Can we use the pharmacy data to estimate the prevalence of chronic conditions? A comparison of multiple data sources. BMC Public Health, 11(1), 688. 10.1186/1471-2458-11-688</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-11-688</ArticleId><ArticleId IdType="pmc">PMC3223740</ArticleId><ArticleId IdType="pubmed">21892946</ArticleId></ArticleIdList></Reference><Reference><Citation>Enners, S., Gradl, G., Kieble, M., Böhm, M., Laufs, U., &amp; Schulz, M. (2021). Utilization of drugs with reports on potential efficacy or harm on COVID-19 before,: During, and after the first pandemic wave. Pharmacoepidemiology and Drug Safety, 30(11), 1493–1503. 10.1002/pds.5324</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5324</ArticleId><ArticleId IdType="pmc">PMC8441787</ArticleId><ArticleId IdType="pubmed">34245078</ArticleId></ArticleIdList></Reference><Reference><Citation>EPHMRA  (2022). EPHMRA Anatomical Classification from https://www.ephmra.org/sites/default/files/2022-01/2022%20ATC%20Guidelines.pdf</Citation></Reference><Reference><Citation>European Society of Cardiology  (March 13, 2020). Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers from https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang</Citation></Reference><Reference><Citation>Fang, L., Karakiulakis, G., &amp; Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine, 8(4), e21. 10.1016/s2213-2600(20)30116-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(20)30116-8</ArticleId><ArticleId IdType="pmc">PMC7118626</ArticleId><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnanenthiran, S. R., Borghi, C., Burger, D., Caramelli, B., Charchar, F., Chirinos, J. A., Cohen, J. B., Cremer, A., Di Tanna, G. L., Duvignaud, A., Freilich, D., Gommans, D. H. F., Gracia-Ramos, A. E., Murray, T. A., Pelorosso, F., Poulter, N. R., Puskarich, M. A., Rizas, K. D., Rothlin, R., … Schutte, A. E. (2022). Renin-Angiotensin system inhibitors in patients with COVID-19: A meta-analysis of randomized controlled trials led by the international society of hypertension. Journal of the American Heart Association, 11(17), e026143. 10.1161/jaha.122.026143</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/jaha.122.026143</ArticleId><ArticleId IdType="pmc">PMC9496439</ArticleId><ArticleId IdType="pubmed">36000426</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes, T., Kim, K. C., Suda, K. J., Garg, R., &amp; Tadrous, M. (2022). International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID-19 pandemic: A cross-sectional analysis of 66 countries. Pharmacoepidemiology and Drug Safety, 31(7), 779–787. 10.1002/pds.5443</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5443</ArticleId><ArticleId IdType="pmc">PMC9088547</ArticleId><ArticleId IdType="pubmed">35460142</ArticleId></ArticleIdList></Reference><Reference><Citation>Guscoth, L., &amp; Hodgson, S. (2021). Analysis of the trend in community prescribing of RAAS inhibitors during the COVID-19 pandemic. The British Journal of Cardiology, 28(4), 44. 10.5837/bjc.2021.044</Citation><ArticleIdList><ArticleId IdType="doi">10.5837/bjc.2021.044</ArticleId><ArticleId IdType="pmc">PMC9063701</ArticleId><ArticleId IdType="pubmed">35747072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidi, N., Tan, Y. R., Jawahir, S., &amp; Tan, E. H. (2021). Determinants of community pharmacy utilisation among the adult population in Malaysia: Findings from the national health and morbidity survey 2019. BMC Health Services Research, 21(1), 649. 10.1186/s12913-021-06656-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-021-06656-1</ArticleId><ArticleId IdType="pmc">PMC8254968</ArticleId><ArticleId IdType="pubmed">34217293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashim, J. H., Adman, M. A., Hashim, Z., Mohd Radi, M. F., &amp; Kwan, S. C. (2021). COVID-19 epidemic in Malaysia: Epidemic progression, challenges, and response. Frontiers in Public Health, 9, 560592. 10.3389/fpubh.2021.560592</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.560592</ArticleId><ArticleId IdType="pmc">PMC8138565</ArticleId><ArticleId IdType="pubmed">34026696</ArticleId></ArticleIdList></Reference><Reference><Citation>Jandoc, R., Burden, A. M., Mamdani, M., Lévesque, L. E., &amp; Cadarette, S. M. (2015). Interrupted time series analysis in drug utilization research is increasing: Systematic review and recommendations. Journal of Clinical Epidemiology, 68(8), 950–956. 10.1016/j.jclinepi.2014.12.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2014.12.018</ArticleId><ArticleId IdType="pubmed">25890805</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden, A. (2015). Conducting interrupted time-series analysis for single- and multiple-group comparisons. The Stata Journal, 15(2), 480–500. 10.1177/1536867(1501500208</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1536867(1501500208</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu, C., Pambrun, E., Bénard-Laribière, A., Noize, P., Faillie, J. L., Bezin, J., &amp; Pariente, A. (2022). Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: A nationwide repeated cohort study. European Journal of Epidemiology, 37(10), 1049–1059. 10.1007/s10654-022-00912-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-022-00912-2</ArticleId><ArticleId IdType="pmc">PMC9490736</ArticleId><ArticleId IdType="pubmed">36129659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health Malaysia (2020). Malaysian statistics on medicines 2015-2016. Pharmaceutical Services Programme.</Citation></Reference><Reference><Citation>Ministry of Health Malaysia (2021). Health facts 2021. Health Informatics Centre, Planning Division.</Citation></Reference><Reference><Citation>Nandi, A., Pecetta, S., &amp; Bloom, D. E. (2023). Global antibiotic use during the COVID-19 pandemic: Analysis of pharmaceutical sales data from 71 countries, 2020-2022. EClinicalMedicine, 57, 101848. 10.1016/j.eclinm.2023.101848</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101848</ArticleId><ArticleId IdType="pmc">PMC9900305</ArticleId><ArticleId IdType="pubmed">36776504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng, S. W., Hwong, W. Y., Husin, M., Ab Rahman, N., Nasir, N. H., Juval, K., &amp; Sivasampu S. (2022). Assessing the availability of teleconsultation and the extent of its use in Malaysian public primary care clinics: Cross-sectional study. JMIR Formative Research, 6(5), e34485. 10.2196/34485</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/34485</ArticleId><ArticleId IdType="pmc">PMC9127641</ArticleId><ArticleId IdType="pubmed">35532973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong, S. M., Lim, M. T., Fah Tong, S., Kamaliah, M. N., Groenewegen, P., &amp; Sivasampu, S. (2022). Comparative performance of public and private primary care service delivery in Malaysia: An analysis of findings from QUALICOPC. PLoS ONE, 17(10), e0276480. 10.1371/journal.pone.0276480</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0276480</ArticleId><ArticleId IdType="pmc">PMC9586414</ArticleId><ArticleId IdType="pubmed">36269717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ontario Drug Policy Research Network  (April 2023). COVID-19 Ontario Prescription Drug Utilization Tool. Retrieved from https://odprn.ca/covid19-ontario-prescription-drug-utilization-tool /</Citation></Reference><Reference><Citation>Prajapati, P., Desai, H., &amp; Chandarana, C. (2022). Hand sanitizers as a preventive measure in COVID-19 pandemic,: its characteristics, and harmful effects: A review. The Journal of the Egyptian Public Health Association, 97(1), 6. 10.1186/s42506-021-00094-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42506-021-00094-x</ArticleId><ArticleId IdType="pmc">PMC8823197</ArticleId><ArticleId IdType="pubmed">35133535</ArticleId></ArticleIdList></Reference><Reference><Citation>Selke Krulichová, I., Selke, G. W., Bennie, M., Hajiebrahimi, M., Nyberg, F., Fürst, J., Garuolienė, K., Poluzzi, E., Slabý, J., Yahni, C. Z., Altini, M., Fantini, M. P., Kočí, V., McTaggart, S., Pontes, C., Reno, C., Rosa, S., Pedrola, M. T., Udovič, M., &amp; Wettermark, B. (2022). Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study. Pharmacoepidemiology and Drug Safety, 31(10), 1046–1055. 10.1002/pds.5509</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5509</ArticleId><ArticleId IdType="pmc">PMC9350215</ArticleId><ArticleId IdType="pubmed">35791700</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen-Crowe, B., McKenney, M., &amp; Elkbuli, A. (2021). Medication shortages during the COVID-19 pandemic: Saving more than COVID lives. The American Journal of Emergency Medicine, 45, 557–559. 10.1016/j.ajem.2020.07.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.07.044</ArticleId><ArticleId IdType="pmc">PMC7378009</ArticleId><ArticleId IdType="pubmed">32763102</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivasampu, S., Wahab, Y. F., Ong, S. M., Ismail, S. A., Goh, P. P., &amp; Jeyaindran, S. (2016). National medical care statistics (NMCS) 2014. National Clinical Research Centre, Ministry of Health Malaysia.</Citation></Reference><Reference><Citation>Suda, K. J., Kim, K. C., Hernandez, I., Gellad, W. F., Rothenberger, S., Campbell, A., Malliart L., &amp; Tadrous M. (2022). The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis. Journal of the American Pharmacists Association, 62(3), 766–774. e766. 10.1016/j.japh.2021.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.japh.2021.12.014</ArticleId><ArticleId IdType="pmc">PMC8704785</ArticleId><ArticleId IdType="pubmed">35094929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sureshkumar, S., Mustapha, F., Yusoff, H., Mwangi, K. J., Marcus, K., Kohlbrenner, B., Issom, D., Benissa, M.-R., Aebischer-Perone, S., Braha, N., Candela, E., Chhabra, K. G., Desikachari, B. R., Dondi, A., Etchebehere, M., Gathecha, G., Kengne, A. P., Missoni, E., Palafox, B., … Etter, J.-F. (2023). An online survey of the perceptions of clinical and non-clinical professionals on healthcare for non-communicable diseases and COVID-19 measures during the pandemic in Malaysia. International Journal of Public Health, 68, 1605861. 10.3389/ijph.2023.1605861</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/ijph.2023.1605861</ArticleId><ArticleId IdType="pmc">PMC10247991</ArticleId><ArticleId IdType="pubmed">37304500</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, C. S., Lokman, S., Rao, Y., Kok, S. H., &amp; Ming, L. C. (2021). Public and private sectors collective response to combat COVID-19 in Malaysia. Journal of Pharmaceutical Policy and Practice, 14(1), 40. 10.1186/s40545-021-00322-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40545-021-00322-x</ArticleId><ArticleId IdType="pmc">PMC8091142</ArticleId><ArticleId IdType="pubmed">33941265</ArticleId></ArticleIdList></Reference><Reference><Citation>Thong, K. S., Selvaratanam, M., Tan, C. P., Cheah, M. F., Oh, H. L., Lee, P. M., Chew, C.-C., Chang, C.-T., &amp; Lee, J. C. Y. (2021). Pharmacy preparedness in handling COVID-19 pandemic: A sharing experience from a Malaysian tertiary hospital. Journal of Pharmaceutical Policy and Practice, 14(1), 61. 10.1186/s40545-021-00343-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40545-021-00343-6</ArticleId><ArticleId IdType="pmc">PMC8286857</ArticleId><ArticleId IdType="pubmed">34275491</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifirò, G., Crisafulli, S., Andò, G., Racagni, G., &amp; Drago, F. (2020). Should patients receiving ACE inhibitors or angiotensin receptor blockers be switched to other antihypertensive drugs to prevent or improve prognosis of novel coronavirus disease 2019 (COVID-19)? Drug Safety, 43(6), 507–509. 10.1007/s40264-020-00935-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-00935-2</ArticleId><ArticleId IdType="pmc">PMC7164333</ArticleId><ArticleId IdType="pubmed">32303915</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, S. L., Forbes, A. B., Karahalios, A., Taljaard, M., &amp; McKenzie, J. E. (2021). Evaluation of statistical methods used in the analysis of interrupted time series studies: A simulation study. BMC Medical Research Methodology, 21(1), 181. 10.1186/s12874-021-01364-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01364-0</ArticleId><ArticleId IdType="pmc">PMC8403376</ArticleId><ArticleId IdType="pubmed">34454418</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2020) WHO Director-General’s opening remarks at the media briefing on COVID-19.</Citation></Reference><Reference><Citation>Yeo, Y. L., Chang, C. T., Chew, C. C., &amp; Rama, S. (2021). Contactless medicine lockers in outpatient pharmacy: A safe dispensing system during the COVID-19 pandemic. Research in Social &amp; Administrative Pharmacy, 17(5), 1021–1023. 10.1016/j.sapharm.2020.11.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sapharm.2020.11.011</ArticleId><ArticleId IdType="pmc">PMC7671646</ArticleId><ArticleId IdType="pubmed">33234450</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunus, S., Puteh, S. E. W., Ali, A. M., &amp; Daud, F. (2021). The COVID impact to public healthcare utilization among urban low-income subsidized community in Klang Valley, Malaysia. Health Services Research and Managerial Epidemiology, 8, 23333928211002407. 10.1177/23333928211002407</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/23333928211002407</ArticleId><ArticleId IdType="pmc">PMC7975447</ArticleId><ArticleId IdType="pubmed">33796627</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>